Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)

This article was originally published in The Pink Sheet Daily

Executive Summary

Wirth discusses personalized medicine and Genzyme’s development pipeline, including further plans for Mozobil.

You may also be interested in...



Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant

NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.

Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant

NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.

Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)

Wirth talks about Genzyme’s contentious acquisition of AnorMED and current shareholder objections to the company’s bid to acquire clofarabine partner Bioenvision.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel